Protocolized Gastrointestinal Fistula Management is Superior to Historic Data and National Averages: A Retrospective Review of an Enterocutaneous Fistula Registry

• Published in: The American surgeon 2024-07, p.31348241265353
• Main Authors: Moore, Lucie, Entelisano, Trina, McKean, Jordan, Vanzant, Erin, Rosenthal, Martin
• Format: Article
• Language: English
• ISSN: 0003-1348; 1555-9823; 1555-9823
• DOI: 10.1177/00031348241265353

Enterocutaneous fistula (ECF) management remains a complex clinical problem. Prehabilitation (prehab) protocols are becoming more popular. The prehabilitation protocol used in this paper was adopted in 2017 at the University of Florida. The Fistula Registry at University of Florida has captured the efforts of the UFAIR (University of Florida Abdominal Wall Reconstruction and Intestinal Rehab) service. We analyzed if the prehabilitation program is successful in reducing deaths, length of stay, recurrence of fistula, and readmissions to the hospital in our database. Charts were queried for patients with ECF/EAF from the UFAIR database from January 1, 2017, until present day. Several factors were recorded including: cause of fistula, recurrence of fistula, wound infection, postoperative sepsis, hospital length of stay, postoperative ICU length of stay, postoperative length of stay, death, discharge disposition, and if taken back to surgery. 31 patients underwent prehabilitation while 30 patients underwent standard nutritional therapy. No deaths were reported in the prehab group, compared to 7 deaths in the standard group ( = .006). The prehab population had an average hospital stay of 15.19 days while the standard group had an average stay of 21.16 days ( = .045). 2/31 in the prehab protocol had a recurrence of ECF while 10/30 in the standard protocol recurred ( = .01). Our study showed promising data for the effects of prehabilitation protocol for patients with ECF. The outcomes of those in the prehab protocol surpassed historical outcomes. Our patients had no deaths, shorter hospital stays, and lower rates of recurrence.